P. Murali Doraiswamy
Professor of Psychiatry and Behavioral Sciences
Murali Doraiswamy MBBS FRCP is Professor of Psychiatry and Professor in Medicine at Duke University School of Medicine where he is a highly cited physician scientist at the Duke Institute for Brain Sciences. He is also a Senior Fellow at the Duke Center for the Study of Aging and an Affiliate Faculty at the Duke Center for Precision Medicine and Applied Genomics as well as the Duke Microbiome Center. He directs a clinical trials unit that has been involved in the development of many modern diagnostic tests, apps, algorithms, and therapeutics in wide use today. Prof Doraiswamy has been an advisor to leading government agencies, businesses and advocacy groups including the NIH, FDA, and WHO as well as numerous life science companies. He has served as the chair of the World Economic Forum’s Global Agenda Council on Brain Research and co-chaired the innovation advisory council for one of the world’s largest social impact funds dedicated to promoting innovative solutions to reverse age related disorders. He has lectured at leading global forums to advance the forefront of aging and neuroscience research. Moreover as an investigator on numerous landmark trials and co-author on more than 400 publications, he has received several awards in recognition of his scientific work. Additionally, he is a leading advocate for increasing funding for brain and behavioral research to help address great looming challenges in society posed by modern developments in the 21st century. His research has been featured in media outlets such as BBC, The New York Times, Scientific American, The Wall Street Journal, National Public Radio, CBS Evening news, The Dr Oz Show, Oprah, and TIME. He has appeared in acclaimed documentaries such as (Dis)Honesty: The Truth about Lies and Mysteries of the Brain. He is the co-author of a popular book The Alzheiemr's Action Plan. Prof. Doraiswamy also serves on the board of several global charities.
Genetic Modulations of Morbidity Compression: A Population-Based Study awarded by National Institutes of Health (Investigator). 2020 to 2025
Duke Creating ADRD Researchers for the Next Generation - Stimulating Access to Research in Residency Program (CARiNG-StARR)" awarded by National Institutes of Health (Preceptor). 2020 to 2024
Racial and Geographic Disparities in Risk and Survival of Alzheimer's Disease and Related Dementias: Effects of Over/UnderDiagnosis and Disease Severity awarded by National Institutes of Health (Senior Investigator). 2019 to 2024
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-AD awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Evaluating Effects in the Relationship between Traumatic Brain Injury and Alzheimer's Disease: Epidemiological Determinants, Their Health-Related Causes and the Resulting Disparities awarded by United States Army Medical Research Acquisition Activity (Senior Investigator). 2020 to 2023
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment awarded by The Trustees of Columbia University (Principal Investigator). 2020 to 2023
Gut Liver Brain Biochemical Axis in Alzheimer's Disease awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to Treatment awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Blueberry supplementation effects in Subjects at Risk for Alzheimer's Disease awarded by U.S. Highbush Blueberry Council (Principal Investigator). 2022 to 2023
ADNI-3 Diversity Supplement awarded by University of Southern California (Principal Investigator). 2020 to 2022
Scott, Jan, et al. “Research to Clinical Practice-Youth seeking mental health information online and its impact on the first steps in the patient journey.” Acta Psychiatr Scand, vol. 145, no. 3, Mar. 2022, pp. 301–14. Pubmed, doi:10.1111/acps.13390. Full Text
Califf, Robert M., et al. “Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study.” Bmj Open, vol. 12, no. 1, Jan. 2022, p. e054741. Pubmed, doi:10.1136/bmjopen-2021-054741. Full Text
Shuren, J., and P. M. Doraiswamy. “Digital Therapeutics for MCI and Alzheimer's disease: A Regulatory Perspective - Highlights From The Clinical Trials on Alzheimer's Disease conference (CTAD).” J Prev Alzheimers Dis, vol. 9, no. 2, 2022, pp. 236–40. Pubmed, doi:10.14283/jpad.2022.28. Full Text
Prescott, Jeffrey W., et al. “Diffusion Tensor MRI Structural Connectivity and PET Amyloid Burden in Preclinical Autosomal Dominant Alzheimer Disease: The DIAN Cohort.” Radiology, vol. 302, no. 1, Jan. 2022, pp. 143–50. Pubmed, doi:10.1148/radiol.2021210383. Full Text
Motter, Jeffrey N., et al. “Cortical thickness predicts remission of depression with antidepressants in patients with late-life depression and cognitive impairment.” J Affect Disord, vol. 295, Dec. 2021, pp. 438–45. Pubmed, doi:10.1016/j.jad.2021.08.062. Full Text
Wang, QuanQiu, et al. “Gut-microbiota-microglia-brain interactions in Alzheimer's disease: knowledge-based, multi-dimensional characterization.” Alzheimers Res Ther, vol. 13, no. 1, Oct. 2021, p. 177. Pubmed, doi:10.1186/s13195-021-00917-1. Full Text
Grzesiak, Emilia, et al. “Assessment of the Feasibility of Using Noninvasive Wearable Biometric Monitoring Sensors to Detect Influenza and the Common Cold Before Symptom Onset.” Jama Netw Open, vol. 4, no. 9, Sept. 2021, p. e2128534. Pubmed, doi:10.1001/jamanetworkopen.2021.28534. Full Text Open Access Copy
Occhipinti, Jo-An, et al. “Mental health: build predictive models to steer policy.” Nature, vol. 597, no. 7878, Sept. 2021, pp. 633–36. Pubmed, doi:10.1038/d41586-021-02581-9. Full Text
Califf, Robert M., et al. “Importance of Social Determinants in Screening for Depression.” J Gen Intern Med, Aug. 2021. Pubmed, doi:10.1007/s11606-021-06957-5. Full Text
James, Olga G., et al. “Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series.” Clin Nucl Med, vol. 46, no. 7, July 2021, pp. 605–08. Pubmed, doi:10.1097/RLU.0000000000003493. Full Text Open Access Copy
Devanand, Davangere P., et al. “THERAPEUTIC STRATEGIES IN DEPRESSION WITH COGNITIVE IMPAIRMENT.” American Journal of Geriatric Psychiatry, vol. 26, no. 3, ELSEVIER SCIENCE INC, 2018, pp. S18–20.
Harenberg, S., et al. “Knowledge-guided maximal clique enumeration.” Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), vol. 10086 LNAI, 2016, pp. 604–18. Scopus, doi:10.1007/978-3-319-49586-6_43. Full Text
Doraiswamy, P. Murali, et al. “Preimplantation Genetic Diagnosis (PGD) for Familial Alzheimer's Disease Due To PSEN1 Mutation.” Annals of Neurology, vol. 76, WILEY-BLACKWELL, 2014, pp. S90–S90.
Hochstetler, Helen, et al. “Relationship of Florbetapir F18 PET Amyloid Plaque Neuroimaging with Future Cognitive Decline over 36 Months.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S136–S136. Crossref, doi:10.1016/j.jagp.2012.12.180. Full Text
Witte, Michael, et al. “Florbetapir PET Imaging Predicts Postmortem Amyloid Burden in Alzheimer's Disease Despite Presence of Other Neuropathologies.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S138–39. Crossref, doi:10.1016/j.jagp.2012.12.183. Full Text
Sheldon, F. C., et al. “Disruption of Functional Brain Connections in Alzheimer's Disease.” Journal of Nuclear Medicine, vol. 51, no. 5, SOC NUCLEAR MEDICINE INC, 2010, pp. 828–29.
Doraiswamy, P. Murali, et al. “In Cognitively Healthy and Mildly Impaired Individuals Florbetapir F 18 PET Measures of Amyloid Deposition Correlate with the Degree of Functional Impairment Assessed Six Months Later.” Neurology, vol. 74, no. 9, LIPPINCOTT WILLIAMS & WILKINS, 2010, pp. A338–A338.
Doraiswamy, P. Murali, et al. “Atypical antipsychotic drugs and diabetes mellitus in the USFDA adverse event reporting system (AERS) database in pediatric and adult patients.” Biological Psychiatry, vol. 63, no. 7, ELSEVIER SCIENCE INC, 2008, pp. 283S-284S.
Kaddurah-Daouk, Rima, et al. “Metabolomic mapping of schizophrenia and atypical antipsychotic effects.” Biological Psychiatry, vol. 61, no. 8, ELSEVIER SCIENCE INC, 2007, pp. 164S-164S.
Szarfman, A., et al. “Risperidone and pituitary tumors: a pharmacovigilance study.” Bipolar Disorders, vol. 7, BLACKWELL PUBLISHING, 2005, pp. 116–17.